Collage Venture Partners

Retension Pharmaceuticals is a healthcare company.Heart disease remains the leading cause of death worldwide. Nearly 50% of adult Americans have elevated blood pressure.

Response Pharmaceuticals is a biotechnology and pharmaceutical company focused on developing innovative treatments for the metabolic side effects associated with antipsychotic medications. The firm is working on an iMTP inhibitor aimed at addressing issues such as weight gain and metabolic dysregulation, which can hinder patients' recovery from mental illness. By targeting these metabolic challenges, Response Pharmaceuticals aims to enhance the overall well-being of patients, enabling them to better manage both their mental health and associated physical health concerns.

Bond Biosciences, Inc. is a biopharmaceutical company based in New York, established in 2015. The company specializes in the development of innovative, non-absorbed oral therapeutics aimed at treating iron overload disorders. Its primary focus is on creating first-in-class chelators that bind excess ions locally in the gastrointestinal tract, allowing for effective management of ion-related diseases. By concentrating on small molecule-based therapeutics, Bond Biosciences aims to provide simpler treatment options for patients suffering from these conditions.

Bond Biosciences, Inc. is a biopharmaceutical company based in New York, established in 2015. The company specializes in the development of innovative, non-absorbed oral therapeutics aimed at treating iron overload disorders. Its primary focus is on creating first-in-class chelators that bind excess ions locally in the gastrointestinal tract, allowing for effective management of ion-related diseases. By concentrating on small molecule-based therapeutics, Bond Biosciences aims to provide simpler treatment options for patients suffering from these conditions.